Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a Phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
J Am Acad Dermatol 2018;79:266–76. doi: 10.1016/j.jaad.2018.04.013
In this phase 3 study, both 200mg and 400mg certolizumab pegol doses improved psoriasis symptoms at Week 12 measured via PASI 75. Improvement was maintained, after rerandomisation, through Week 48, with a safety profile consistent with its drug class. This Phase 3 CIMPACT trial by Lebwohl et al., assessed the safety and efficacy of certolizumab pegol for the treatment of moderate-to-severe chronic plaque psoriasis.
All endpoints were significantly greater for certolizumab versus placebo with the greatest response seen in 400mg. Etanercept was inferior to certolizumab pegol 400mg and noninferior to 200mg certolizumab pegol.
